Group 1 - China Pacific Insurance's subsidiary, China Pacific Life, reported a cumulative premium income of 241.32 billion yuan for the first ten months, a year-on-year increase of 9.9% [1] - China Pacific Property Insurance, another subsidiary, achieved a cumulative premium income of 173.57 billion yuan, with a year-on-year growth of 0.4% [1] - Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters, despite a revenue increase of 59.85% to 1.115 billion yuan [1] Group 2 - Founder Securities received approval from the China Securities Regulatory Commission to issue short-term corporate bonds not exceeding 5 billion yuan [1] - Haicheng Bonda's director plans to reduce his stake by up to 0.97%, equating to 198,400 shares [1] - Yuyuan Group intends to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 8.60 yuan per share [1] Group 3 - Huaren Shuanghe's subsidiary passed the GMP compliance inspection for a specific diabetes medication [4] - Lichong Group received project notifications from three international automotive manufacturers, with expected sales amounting to approximately 1.135 billion yuan [6] - Deyang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [7] Group 4 - Longxin General announced the transfer of its entire stake in a subsidiary for 105.6 million yuan, and also plans to divest another stake for 1 yuan due to poor performance [16] - Kangda New Materials decided to terminate the acquisition of a semiconductor company due to unsatisfactory due diligence progress [17] - Lu'an Environmental reported a 3.28% year-on-year increase in coal sales for October, totaling 3.78 million tons [18] Group 5 - Shanghai Port Group plans to invest 2 billion yuan to establish a new holding company with several state-owned enterprises [20] - Borui Pharmaceutical's new drug for obesity treatment has received clinical trial approval [23] - Silver Dragon Co. has completed the registration of a new energy industry fund focusing on high-growth potential projects [24] Group 6 - Hengrui Medicine received approval for a clinical trial of a prostate cancer drug [11] - Baiji Shenzhou reported a net profit of 1.139 billion yuan for the first three quarters, marking a turnaround from losses [36] - Huasheng Pharmaceutical's special medical food product has received registration certification [60]

公司核心产品奥布替尼(宜诺凯® )销售收入持续增长，2025 年 1-9 月共实现其销售收入 10.10 亿元，同 比增长 45.77%。 智通财经APP讯，诺诚健华(09969)公布2025年第三季度业绩，营业收入约3.84亿元，同比增长38.09%; 归属于上市公司股东的净亏损为3432.35万元，基本每股亏损0.02元。1-9月，营业收入为约11.15亿元， 同比增长59.85%;归属于上市公司股东的净亏损约6441.49万元，同比收窄76.61%。 ...

Core Insights - The company reported a 59.8% year-on-year increase in total revenue for the first three quarters of 2025, reaching 1.12 billion RMB, driven by the continued growth in sales of its core product, BTK inhibitor Oubatinib (Yinokai®), and an upfront payment from a licensing agreement with Prolium [1] Revenue Performance - Oubatinib's revenue for the first three quarters increased by 45.8% year-on-year, amounting to 1.01 billion RMB, surpassing the total revenue of the previous year, attributed to the expanding market for its exclusive indication of marginal zone lymphoma (MZL) and the approval of new indications for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) [1] Loss Reduction - The company's losses significantly narrowed by 74.8%, reducing to 0.07 billion RMB, primarily due to rapid revenue growth and improved cost efficiency [1]

诺诚健华医药有限公司管理层评论说：公司是一家以卓越的自主研发能力为核心驱动力的高科技创新生 物医药企业，拥有全面的研发、生产和商业化能力，专注于肿瘤和自身免疫性疾病等存在巨大未满足临 床需求的领域，在全球市场内开发具有突破性潜力的同类首创或同类最佳药物。 格隆汇11月13日丨诺诚健华(09969.HK)公告，2025年1-9月公司总营业收入11.15亿元，比上年同期增长 59.85%，毛利率为88.8%，比上年同期的86.0%提高了2.8个百分点。营业收入与毛利率的高速增长主要 为核心产品奥布替尼(宜诺凯)销售收入持续增长以及公司与Prolium Bioscience Inc.(以下简称"Prolium") 达成授权许可的首付款所致。公司2025年1-9月的净亏损为0.72亿元，比上年同期亏损收窄74.78%。 ...

崔霽松博士 （主席兼行政總裁） 趙仁濱博士 非執行董事 InnoCare Pharma Limited 諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） 董事名單與其角色及職能 諾誠健華醫藥有限公司（「本公司」）董事會（「董事會」）成員載列如下： 執行董事 施一公博士 謝榕剛先生 獨立非執行董事 胡蘭女士 董丹丹博士 管坤良教授 董事會設立三個董事委員會。下表載列各董事會成員在該等委員會中所擔任 的職位： | | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | | 崔霽松博士 | | M | C | | 趙仁濱博士 | | | | | 施一公博士 | | | | | 謝榕剛先生 | M | | | | 胡蘭女士 | C | C | | | 董丹丹博士 | M | M | M | | 管坤良教授 | | | M | 附註： C 相關董事會轄下委員會的主席 M 相關董事會轄下委員會的成員 香港，2025年11月13日（星期四） ...

InnoCare Pharma Limited 諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） (1)2025年第三季度季度報告 及 (2)提名委員會組成變動 本 公 告 乃 由 諾 誠 健 華 醫 藥 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第 13.09(2)(a)條及第13.10B條及香港法例第571章證券及期貨條例第XIVA部的內幕 消息條文作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 2025年第三季度季度報告 茲載列本公司在上海證券交易所網站刊發的《諾誠健華醫藥有限公司2025年第 三季度報告》（「2025年第三季度報告」），僅供參閱。以下為本公司2025年第三 季度報告的原文，僅供參考。如有任何歧義，概以中文版本為準。 本公司董事（「董事」）會（「董事會」）提醒 ...

关于调整董事会提名委员会成员的公告 诺诚健华医药有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | A | 股代码：688428 | 股简称：诺诚健华 A | 公告编号：2025-038 | | --- | --- | --- | --- | | 港股代码：09969 | | 港股简称：诺诚健华 | | | | 调整前 | Jisong | Cui（崔霁松）博士（主席）、胡兰女士、 | | --- | --- | --- | --- | | 董事会提名 | | 董丹丹博士 | | | 委员会 | 调整后 | Jisong | Cui（崔霁松）博士（主席）、董丹丹博士、 | | | | Kunliang | Guan（管坤良）教授 | 特此公告。 诺诚健华医药有限公司董事会 2025 年 11 月 14 日 1 诺诚健华医药有限公司（以下简称"公司"）于 2025 年 11 月 13 日召开董事 会，审议通过《提名委员会成员变动》的议案，现将有关情况公告如下： 鉴于香港联交所上市规则附录 C1 所载企业管治守则的修 ...

Core Viewpoint - Nocera Biopharma (688428) reported significant revenue growth and reduced net loss in Q3 2025, indicating a positive trajectory towards profitability and sustainable growth [1] Financial Performance - The company achieved a revenue of 1.115 billion yuan in the first three quarters, representing a year-on-year increase of 59.85% [1] - The net loss for the same period was 72 million yuan, which is a 74.78% reduction compared to the previous year [1] Revenue Drivers - The revenue growth was primarily driven by the continued sales increase of the core product, BTK inhibitor Acalabrutinib (Yinokai), and an upfront payment from a licensing agreement with Prolium [1] - Acalabrutinib's revenue for the first three quarters rose by 45.8% year-on-year, reaching 1.01 billion yuan, surpassing the total revenue of the previous year [1] Future Outlook - The company anticipates achieving breakeven for the full year 2025, two years ahead of its profitability target, supported by strong revenue growth, strict cost management, and a significant licensing deal with Zenas in early October [1] - This positions the company well for sustainable profitability and accelerated globalization [1]

Financial Performance - The total operating revenue for the first nine months of 2025 reached RMB 1.115 billion, an increase of 59.85% compared to the same period last year, with a gross margin of 88.8%, up 2.8 percentage points from 86.0%[4] - Sales revenue from the core product, Orelabrutinib (宜诺凯®), amounted to RMB 1.010 billion for the first nine months of 2025, representing a year-on-year growth of 45.77%[5] - The company reported a significant increase in operating revenue, primarily due to the continuous increase in sales volume of a key product, resulting in a substantial cash inflow[12] - Total revenue for the first three quarters of 2025 reached CNY 1,115,328,393.86, a significant increase of 60% compared to CNY 697,748,228.93 in the same period of 2024[21] - The company's total revenue from drug sales for the first nine months of 2025 was RMB 1.024 billion, an increase of 47.38% year-on-year[7] Expenses and Losses - The net loss for the first nine months of 2025 was RMB 72 million, a reduction of 74.78% compared to the same period last year[4] - Research and development expenses totaled RMB 676 million for the first nine months of 2025, accounting for 60.61% of operating revenue, a decrease of 27.53 percentage points year-on-year[7] - The net loss for the first three quarters of 2025 was CNY 71,950,523.03, an improvement from a net loss of CNY 285,317,584.04 in the same period of 2024[22] - The company experienced a net loss attributable to shareholders, with basic and diluted earnings per share showing a decline compared to the same period last year[12] - The company reported a basic and diluted earnings per share of CNY -0.04 for the first three quarters of 2025, compared to CNY -0.16 in 2024[22] Cash Flow and Assets - As of September 30, 2025, the company held approximately RMB 7.759 billion in cash and cash equivalents, enabling continued acceleration of pipeline project development[6] - The company's cash and cash equivalents increased to CNY 6,820,269,250.58 as of September 30, 2025, compared to CNY 6,240,825,867.22 at the end of 2024[19] - The total assets as of September 30, 2025, were CNY 9,523,812,210.96, up from CNY 9,407,493,740.91 at the end of 2024[20] - The total cash and cash equivalents at the end of the period decreased to CNY 4,382,410,146.31 from CNY 4,949,637,182.02 year-over-year[24] - The company reported a cash outflow of CNY 1,389,806,235.54 from operating activities, compared to CNY 1,220,717,440.28 in the previous year[24] Shareholder Information - The total number of shares issued by the company is 1,764,643,952, with 1,496,284,235 shares (approximately 84.79%) listed in Hong Kong and 268,359,717 shares (approximately 15.21%) listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board[13] - HKSCC NOMINEES LIMITED holds 892,010,619 shares, representing 50.549% of the total shares[16] - HHLR Fund, L.P. and its concerted parties hold 208,671,222 shares, accounting for 11.8251% of the total shares[17] - Sunny View Holdings and the Zhao family hold 144,817,893 shares, which is 8.2066% of the total shares[17] - The top ten shareholders' holdings were disclosed, with HKSCC NOMINEES LIMITED being the largest shareholder[16] Research and Development - Orelabrutinib was approved for a new indication in April 2025 for first-line treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in adult patients[5] - Research and development expenses amounted to CNY 676,047,531.53, compared to CNY 614,983,375.71 in the previous year, indicating a focus on innovation[21] - The company is actively pursuing market expansion and innovation strategies, as indicated by the increase in R&D spending and overall revenue growth[21] Government Support - The company received government subsidies amounting to RMB 28.17 million for the year-to-date period, contributing to non-operating income[10] Cash Flow Activities - The cash inflow from operating activities increased significantly, driven by higher cash receipts from product sales and upfront payments from licensing agreements[12] - In the first three quarters of 2025, the cash inflow from operating activities was CNY 1,305,468,105.49, a significant increase of 47% compared to CNY 887,581,258.65 in the same period of 2024[24] - The net cash flow from operating activities was negative at CNY -84,338,130.05, an improvement from CNY -333,136,181.63 in the previous year[24] - Cash inflow from investment activities reached CNY 8,250,925,494.08, up from CNY 4,648,580,477.88, marking a growth of 77% year-over-year[24] - The net cash flow from investment activities was CNY -321,499,940.72, a decline from CNY 1,358,936,924.87 in the same period last year[24] - Cash inflow from financing activities totaled CNY 363,355,524.15, down from CNY 1,083,202,214.00 in the previous year[24] - The net cash flow from financing activities was CNY 138,210,016.73, a recovery from CNY -261,692,786.26 in the same period of 2024[24] Accounting Standards - The company did not apply new accounting standards for the year 2025[25]

智通财经APP讯，诺诚健华(688428.SH)披露2025年第三季度报告，公司前三季度实现营收11.15亿元， 同比增长59.85%;归属于上市公司股东的净利润亏损6441万元;扣非净利润亏损1.35亿元;基本每股收 益-0.04元。 ...